DK1648505T3 - Quil A-fraktion med lav toksicitet og anvendelse deraf - Google Patents

Quil A-fraktion med lav toksicitet og anvendelse deraf

Info

Publication number
DK1648505T3
DK1648505T3 DK04749076T DK04749076T DK1648505T3 DK 1648505 T3 DK1648505 T3 DK 1648505T3 DK 04749076 T DK04749076 T DK 04749076T DK 04749076 T DK04749076 T DK 04749076T DK 1648505 T3 DK1648505 T3 DK 1648505T3
Authority
DK
Denmark
Prior art keywords
quil
fraction
adjuvant
lps
derivatives
Prior art date
Application number
DK04749076T
Other languages
Danish (da)
English (en)
Inventor
Kefie Hu
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Katarina Ranlund
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Application granted granted Critical
Publication of DK1648505T3 publication Critical patent/DK1648505T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK04749076T 2003-07-07 2004-07-07 Quil A-fraktion med lav toksicitet og anvendelse deraf DK1648505T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof
PCT/SE2004/001038 WO2005002620A1 (fr) 2003-07-07 2004-07-07 Fraction de quil a a faible toxicite, utilisation de cette derniere

Publications (1)

Publication Number Publication Date
DK1648505T3 true DK1648505T3 (da) 2009-12-21

Family

ID=27731119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04749076T DK1648505T3 (da) 2003-07-07 2004-07-07 Quil A-fraktion med lav toksicitet og anvendelse deraf

Country Status (15)

Country Link
US (8) US8821881B2 (fr)
EP (1) EP1648505B1 (fr)
JP (1) JP4731475B2 (fr)
AT (1) ATE442164T1 (fr)
AU (1) AU2004254152B2 (fr)
BR (1) BRPI0412444B8 (fr)
CA (1) CA2529363C (fr)
DE (1) DE602004023089D1 (fr)
DK (1) DK1648505T3 (fr)
ES (1) ES2331952T3 (fr)
NZ (1) NZ544299A (fr)
PL (1) PL1648505T3 (fr)
SE (1) SE0301998D0 (fr)
WO (1) WO2005002620A1 (fr)
ZA (1) ZA200600151B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1104306E (pt) * 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US8007806B2 (en) 2005-01-20 2011-08-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP1764369A1 (fr) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vaccins comprenant la protéine du noyau du HBV tronquée ainsi qu'un adjuvant à base de saponine
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP1902727A1 (fr) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vaccins comprenant la protéine du noyau du HBV tronquée ainsi qu'un adjuvant à base de saponine
WO2008031878A1 (fr) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Composition pour la thérapie et/ou pour la prophylaxie d'infections au vhb et de maladies dont la médiation est assurée par le vhb
DK2094278T3 (en) * 2006-11-20 2017-07-24 Duecom USE OF LIPID-CONTAINING PARTICLES INCLUDING QUILLAJA SAPONINS FOR CANCER TREATMENT
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
CN102470168A (zh) * 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
DK2750683T4 (da) * 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
EP3566714A1 (fr) 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Vaccins contre la grippe et utilisations associées
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014135651A1 (fr) 2013-03-08 2014-09-12 Crucell Holland B.V. Vaccin acellulaire contre la coqueluche
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
EA034639B1 (ru) 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
WO2015000831A1 (fr) 2013-07-02 2015-01-08 Crucell Holland B.V. Procédé pour la préparation de virosomes
WO2015000832A1 (fr) 2013-07-02 2015-01-08 Crucell Holland B.V. Procédé de préparation de virosomes
UA130246C2 (uk) 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
US10538557B2 (en) 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
CA2996007A1 (fr) 2015-09-03 2017-03-09 Novavax, Inc. Compositions vaccinales ayant une stabilite et une immunogenicite ameliorees
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
DE202016003070U1 (de) 2016-05-09 2016-06-07 Clariant International Ltd. Stabilisatoren für Silikatfarben
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
WO2017207477A1 (fr) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Protéines f du vrs de pré-fusion solubles stabilisées
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2018011196A1 (fr) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Vaccins contre le hpv
CN109906411B (zh) 2016-11-04 2022-12-27 卡博特公司 含结晶聚酯和有机硅的纳米复合物
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
LT3743106T (lt) 2018-01-23 2022-09-26 Janssen Vaccines & Prevention B.V. Gripo viruso vakcinos ir jų panaudojimo būdai
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
CA3098103A1 (fr) 2018-05-23 2019-11-28 Adc Therapeutics Sa Adjuvant moleculaire
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
US20220204567A1 (en) 2019-04-25 2022-06-30 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
JP2022532742A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
WO2020229577A1 (fr) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus
CA3152957A1 (fr) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Vaccins contre le virus de la grippe et leurs utilisations
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
KR20230009466A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 SARS-CoV-2 백신
CA3183086A1 (fr) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Proteines de fusion de proteine de spicule de coronavirus stabilisees
WO2021229448A1 (fr) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Réplicon d'arn codant pour une protéine de spicule de coronavirus stabilisée
US20230233661A1 (en) 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection
US20230302119A1 (en) 2020-07-06 2023-09-28 Janssen Pharmaceuticals, Inc. Stabilized Corona Virus Spike Protein Fusion Proteins
JP7822149B2 (ja) 2020-10-02 2026-03-02 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (fr) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial
WO2022175477A1 (fr) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Antigènes fb de vrs de pré-fusion stabilisés
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
KR20230165275A (ko) 2021-04-01 2023-12-05 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 piv3 f 단백질
WO2023020939A1 (fr) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Vaccins contre le sars-cov-2
WO2023047348A1 (fr) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Protéines de fusion de protéine de spicule de coronavirus stabilisées
WO2023047349A1 (fr) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Protéines de fusion protéines de spicule de coronavirus stabilisées
WO2023111725A1 (fr) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Vaccins anti-sars-cov-2
EP4448802A1 (fr) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Protéines de fusion hmpv pré-hybrides stabilisées
WO2023196634A2 (fr) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
KR20250010642A (ko) 2022-05-12 2025-01-21 엠에스디 인터내셔널 비즈니스 게엠베하 안정화된 융합-전 hmpv 융합 단백질
WO2024017682A1 (fr) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Immunogènes du vrs
EP4565604A2 (fr) 2022-08-01 2025-06-11 Flagship Pioneering Innovations VII, LLC Protéines immunomodulatrices et méthodes associées
WO2024061757A1 (fr) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Protéines f du piv1 humain en pré-fusion
WO2024061759A1 (fr) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Protéines s de coronavirus stabilisées
WO2024061753A1 (fr) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Protéines de fusion de classe i trimères stabilisées
WO2024074584A1 (fr) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Protéines f du piv3 sous forme pré-fusion stabilisées
CN120202213A (zh) 2022-11-14 2025-06-24 扬森疫苗与预防有限公司 乙型流感病毒疫苗及其用途
WO2024151583A2 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024167885A1 (fr) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Compositions immunomodulatrices et procédés associés
KR20250152090A (ko) 2023-02-21 2025-10-22 엠에스디 인터내셔널 비즈니스 게엠베하 이종 삼량체화 도메인이 없는 안정화된 삼량체 rsv 융합 단백질
WO2024258829A1 (fr) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Compositions de vaccin contre le sars-cov-2 et procédés associés
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025163460A2 (fr) 2024-01-30 2025-08-07 Pfizer Inc. Vaccins contre des maladies respiratoires
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (fr) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Protéines de ciblage d'immunorécepteurs et procédés associés
WO2026018181A1 (fr) 2024-07-17 2026-01-22 Pfizer Inc. Compositions immunogènes et leurs utilisations
WO2026038177A1 (fr) 2024-08-16 2026-02-19 Pfizer Inc. Compositions immunogènes et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839376B2 (ja) * 1978-10-30 1983-08-30 富士通株式会社 イオン注入法
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
US20150320858A1 (en) 2015-11-12
PL1648505T3 (pl) 2010-02-26
ATE442164T1 (de) 2009-09-15
US20220241408A1 (en) 2022-08-04
US20160184427A1 (en) 2016-06-30
CA2529363A1 (fr) 2005-01-13
JP4731475B2 (ja) 2011-07-27
BRPI0412444B1 (pt) 2016-06-14
US8821881B2 (en) 2014-09-02
AU2004254152A1 (en) 2005-01-13
US20200345840A1 (en) 2020-11-05
US12171828B2 (en) 2024-12-24
SE0301998D0 (sv) 2003-07-07
EP1648505A1 (fr) 2006-04-26
BRPI0412444A (pt) 2006-09-19
ES2331952T3 (es) 2010-01-21
DE602004023089D1 (de) 2009-10-22
US20140335049A1 (en) 2014-11-13
WO2005002620A1 (fr) 2005-01-13
AU2004254152B2 (en) 2009-10-29
JP2007527386A (ja) 2007-09-27
US20060239963A1 (en) 2006-10-26
EP1648505B1 (fr) 2009-09-09
ZA200600151B (en) 2007-01-31
US20240024468A1 (en) 2024-01-25
NZ544299A (en) 2009-03-31
US20180369368A1 (en) 2018-12-27
CA2529363C (fr) 2013-04-02
BRPI0412444B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
DK1648505T3 (da) Quil A-fraktion med lav toksicitet og anvendelse deraf
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
Barr et al. ISCOMs and other saponin based adjuvants
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2007109812A3 (fr) Composes de potentialisation immunitaire
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
UA94900C2 (uk) Вакцина
WO2006086449A3 (fr) Thiazoloquinolines et thiazolonaphthyridines a substitution alcoxy
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
MX2007003078A (es) Compuestos de imidazoquinolina.
BR122018075729B8 (pt) flavivírus na preparação de uma composição de vacina
WO2009095226A3 (fr) Acides nucléiques de formule (i) (n<sb>u</sb>g<sb>l</sb>x<sb>m</sb>g<sb>n</sb>n<sb>v</sb>)<sb>a</sb> et leurs dérivés sous forme d'immunostimulant/adjuvant
NO20070746L (no) Anvendelse av fosfaterte alkanoler som dispergente , emulgatorer, hydrotroper, fuktmidler og kompatabilitetsstoffer i blandinger for jordbruket.
AR044696A1 (es) Composicion de vacunas
WO2016179034A3 (fr) Procédés et compositions permettant de stimuler une réponse immunitaire à l'aide de motifs d'arn immunostimulateurs puissants
BRPI0511026C1 (pt) uso de um los neisserial, e, composição
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
EP1905449A3 (fr) Composition adjuvante continant une saponine et un oligonucleotide immunostimulateur
SG147465A1 (en) Vaccine
RU99108701A (ru) Растительный иммуностимулятор
WO2001035994A3 (fr) Immunostimulation induite par le chitosane